Tandem Diabetes Care (TNDM) TD Cowen 46th Annual Health Care Conference summary
Event summary combining transcript, slides, and related documents.
TD Cowen 46th Annual Health Care Conference summary
4 Mar, 2026Strategic transformation and business model evolution
Shifted focus to monetizing the sales force, launching innovative products, and expanding market access via the pharmacy channel, with significant IT infrastructure investments to support direct operations in Europe and new country launches in 2025 and 2027.
Introduced PAYGO (pay-as-you-go) model, offering pumps at $0 and supplies at $350/month, aiming to double reimbursement over four years and drive revenue and profitability growth.
Transition to pharmacy channel is phased, with targeted marketing based on coverage, aiming for 20% of pumps and 10% of supplies through pharmacy in 2026, while 80% remains under DME.
PAYGO model reduces patient and physician friction, improves access, and lessens reliance on upfront renewals, shifting revenue to recurring supply sales.
Large installed base provides an advantage in converting customers to the new model, offsetting headwinds from pump giveaways.
Product innovation and pipeline
Launched Control-IQ+, FreeStyle Libre 3 integration, and Android support for Mobi in 2025, with ongoing feature additions.
Mobi Tubeless, featuring SteadiSet seven-day infusion technology, is set for second-half commercialization in 2026, offering extended wear and flexibility between tubed and tubeless use.
Fully closed loop algorithm, developed with UVA, is entering pivotal studies in 2026, targeting commercial launch in late 2027 or early 2028, aiming to reduce patient burden and simplify use for both patients and primary care physicians.
Continued focus on algorithm enhancements and a robust innovation pipeline, including a smaller Tubeless Mobi version in the future.
Sales force and market access
Expanded and restructured sales force with new leadership and CRM systems, emphasizing data-driven productivity and automation.
Pharmacy contracting efforts have resulted in 80% PBM coverage and one-third formulary coverage, with ongoing relationship-building and off-cycle negotiations to expand access.
Sales force productivity expected to increase due to reduced administrative burden and automation, supporting 10-11% pump shipment growth in 2026, with more than half from renewals.
Latest events from Tandem Diabetes Care
- Pharmacy channel shift and new product launches are set to drive margin and volume growth.TNDM
Oppenheimer 36th Annual Healthcare MedTech & Services Conference18 Mar 2026 - Strategic shift to pharmacy and direct sales drives future growth amid record Q4 results.TNDM
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026 - Innovative insulin pump platforms and digital tools drive growth in a large, underpenetrated market.TNDM
Corporate presentation24 Feb 2026 - Innovative pump platforms and digital tools drive growth in a large, underpenetrated diabetes market.TNDM
Corporate presentation24 Feb 2026 - Innovative pump platforms and digital tools drive growth in a large, underpenetrated diabetes market.TNDM
Corporate presentation24 Feb 2026 - Q2 sales up 13% YoY to $221.9M, with 51% gross margin and raised 2024 guidance.TNDM
Q2 202424 Feb 2026 - Record Q3 sales of $244M and raised 2024 guidance reflect strong growth and improved margins.TNDM
Q3 202424 Feb 2026 - Advanced insulin pumps and digital platforms drive growth in a large, underpenetrated market.TNDM
Corporate presentation24 Feb 2026 - Record sales, margin gains, and innovation drive double-digit growth outlook for 2025.TNDM
Q4 202424 Feb 2026